Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186196 | 0.90 | TUBB4A (0.42) | MAPTKDRKMT2ARAB9ADYRK1A | |
| SCHEMBL4173385 | 0.86 | ALDH1A1 (0.41) | MAPTPOLBKDM4ERAB9A | |
| SCHEMBL4181134 | 0.86 | KDM4E (0.44) | MAPTKMT2AKDM4E | |
| SCHEMBL4180853 | 0.80 | KCNA5 (0.40) | AURKAKDM4EDYRK1A | |
| SCHEMBL4170892 | 0.80 | TUBB4A (0.42) | MAPTKDRKMT2A | |
| SCHEMBL4181712 | 0.80 | FYN (0.42) | MAPTKDRKDM4ERAB9A | |
| SCHEMBL4172618 | 0.78 | KCNA5 (0.48) | MAPTAURKAKDM4ERAB9ADYRK1A | |
| SCHEMBL4178015 | 0.75 | CYP3A4 (0.47) | MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL4175489 | 0.74 | NPY5R (0.47) | MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL4177009 | 0.72 | TUBB4A (0.53) | MAPTKMT2AKDM4ERAB9ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | MAPT 3261/4885ACVR1 3275/4885PDE10A 3174/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | MAPT 3261/4885ACVR1 3275/4885PDE10A 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.